147 related articles for article (PubMed ID: 34679238)
1. Identification of an AXL kinase inhibitor in triple-negative breast cancer by structure-based virtual screening and bioactivity test.
Li P; Niu Y; Li S; Zu X; Xiao M; Yin L; Feng J; He J; Shen Y
Chem Biol Drug Des; 2022 Feb; 99(2):222-232. PubMed ID: 34679238
[TBL] [Abstract][Full Text] [Related]
2. Combined inhibition of AXL, Lyn and p130Cas kinases block migration of triple negative breast cancer cells.
Pénzes K; Baumann C; Szabadkai I; Orfi L; Kéri G; Ullrich A; Torka R
Cancer Biol Ther; 2014; 15(11):1571-82. PubMed ID: 25482942
[TBL] [Abstract][Full Text] [Related]
3. Global phosphotyrosine survey in triple-negative breast cancer reveals activation of multiple tyrosine kinase signaling pathways.
Wu X; Zahari MS; Ma B; Liu R; Renuse S; Sahasrabuddhe NA; Chen L; Chaerkady R; Kim MS; Zhong J; Jelinek C; Barbhuiya MA; Leal-Rojas P; Yang Y; Kashyap MK; Marimuthu A; Ling M; Fackler MJ; Merino V; Zhang Z; Zahnow CA; Gabrielson E; Stearns V; Roa JC; Sukumar S; Gill PS; Pandey A
Oncotarget; 2015 Oct; 6(30):29143-60. PubMed ID: 26356563
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic Landscape of AXL Receptor Kinase in Triple-Negative Breast Cancer.
Ozyurt R; Ozpolat B
Mol Cancer Ther; 2023 Jul; 22(7):818-832. PubMed ID: 37028809
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic activity of DCC-2036, a novel tyrosine kinase inhibitor, against triple-negative breast cancer patient-derived xenografts by targeting AXL/MET.
Shen Y; Zhang W; Liu J; He J; Cao R; Chen X; Peng X; Xu H; Zhao Q; Zhong J; Ding W; Lei X; Jiang Y; Zu X
Int J Cancer; 2019 Feb; 144(3):651-664. PubMed ID: 30289981
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic Activity of Anti-AXL Antibody against Triple-Negative Breast Cancer Patient-Derived Xenografts and Metastasis.
Leconet W; Chentouf M; du Manoir S; Chevalier C; Sirvent A; Aït-Arsa I; Busson M; Jarlier M; Radosevic-Robin N; Theillet C; Chalbos D; Pasquet JM; Pèlegrin A; Larbouret C; Robert B
Clin Cancer Res; 2017 Jun; 23(11):2806-2816. PubMed ID: 27923843
[No Abstract] [Full Text] [Related]
7. Design, synthesis and biological evaluation of new Axl kinase inhibitors containing 1,3,4-oxadiazole acetamide moiety as novel linker.
Xu C; Han Y; Xu S; Wang R; Yue M; Tian Y; Li X; Zhao Y; Gong P
Eur J Med Chem; 2020 Jan; 186():111867. PubMed ID: 31757525
[TBL] [Abstract][Full Text] [Related]
8. 4-Oxo-1,4-dihydroquinoline-3-carboxamide Derivatives as New Axl Kinase Inhibitors.
Tan L; Zhang Z; Gao D; Luo J; Tu ZC; Li Z; Peng L; Ren X; Ding K
J Med Chem; 2016 Jul; 59(14):6807-25. PubMed ID: 27379978
[TBL] [Abstract][Full Text] [Related]
9. Activation of HER3 interferes with antitumor effects of Axl receptor tyrosine kinase inhibitors: suggestion of combination therapy.
Torka R; Pénzes K; Gusenbauer S; Baumann C; Szabadkai I; Őrfi L; Kéri G; Ullrich A
Neoplasia; 2014 Apr; 16(4):301-18. PubMed ID: 24862757
[TBL] [Abstract][Full Text] [Related]
10. Quinolone antibiotic derivatives as new selective Axl kinase inhibitors.
Tan L; Zhang Z; Gao D; Chan S; Luo J; Tu ZC; Zhang ZM; Ding K; Ren X; Lu X
Eur J Med Chem; 2019 Mar; 166():318-327. PubMed ID: 30731400
[TBL] [Abstract][Full Text] [Related]
11. Discovery of AXL Degraders with Improved Potencies in Triple-Negative Breast Cancer (TNBC) Cells.
He R; Song Z; Bai Y; He S; Huang J; Wang Y; Zhou F; Huang W; Guo J; Wang Z; Tu ZC; Ren X; Zhang Z; Xu J; Ding K
J Med Chem; 2023 Feb; 66(3):1873-1891. PubMed ID: 36695404
[TBL] [Abstract][Full Text] [Related]
12. The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl.
Dine JL; O'Sullivan CC; Voeller D; Greer YE; Chavez KJ; Conway CM; Sinclair S; Stone B; Amiri-Kordestani L; Merchant AS; Hewitt SM; Steinberg SM; Swain SM; Lipkowitz S
Breast Cancer Res Treat; 2016 Jan; 155(2):235-51. PubMed ID: 26759246
[TBL] [Abstract][Full Text] [Related]
13. MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents.
McDaniel NK; Cummings CT; Iida M; Hülse J; Pearson HE; Vasileiadi E; Parker RE; Orbuch RA; Ondracek OJ; Welke NB; Kang GH; Davies KD; Wang X; Frye SV; Earp HS; Harari PM; Kimple RJ; DeRyckere D; Graham DK; Wheeler DL
Mol Cancer Ther; 2018 Nov; 17(11):2297-2308. PubMed ID: 30093568
[TBL] [Abstract][Full Text] [Related]
14. Recent discovery and development of AXL inhibitors as antitumor agents.
Liu Z; Chen L; Zhang J; Yang J; Xiao X; Shan L; Mao W
Eur J Med Chem; 2024 Jun; 272():116475. PubMed ID: 38714043
[TBL] [Abstract][Full Text] [Related]
15. Accelerating AXL targeting for TNBC therapy.
Khera L; Lev S
Int J Biochem Cell Biol; 2021 Oct; 139():106057. PubMed ID: 34403827
[TBL] [Abstract][Full Text] [Related]
16. Research Progress of Axl Inhibitors.
Sun ZG; Liu JH; Zhang JM; Qian Y
Curr Top Med Chem; 2019; 19(15):1338-1349. PubMed ID: 31218961
[TBL] [Abstract][Full Text] [Related]
17. High-throughput high-content imaging assays for identification and characterization of selective AXL pathway inhibitors.
Tang H; Yang J; Shen DR; Calambur D; Witmer M; Wu S; Carpenter B; Zhang Y; Gao M; Constantine K; Zhang L; Cvijic ME
Assay Drug Dev Technol; 2014; 12(1):80-6. PubMed ID: 24547742
[TBL] [Abstract][Full Text] [Related]
18. Protein kinase C α is involved in the regulation of AXL receptor tyrosine kinase expression in triple-negative breast cancer cells.
Yue CH; Liu LC; Kao ES; Lin H; Hsu LS; Hsu CW; Lin YY; Lin YS; Liu JY; Lee CJ
Mol Med Rep; 2016 Aug; 14(2):1636-42. PubMed ID: 27357025
[TBL] [Abstract][Full Text] [Related]
19. Development of the phenylpyrazolo[3,4-
Lee HJ; Pham PC; Pei H; Lim B; Hyun SY; Baek B; Kim B; Kim Y; Kim MH; Kang NW; Min HY; Kim DD; Lee J; Lee HY
Theranostics; 2021; 11(4):1918-1936. PubMed ID: 33408789
[No Abstract] [Full Text] [Related]
20. Fragment-based lead discovery of indazole-based compounds as AXL kinase inhibitors.
Ng PS; Foo K; Sim S; Wang G; Huang C; Tan LH; Poulsen A; Liu B; Tee DHY; Ahmad NHB; Wang S; Ke Z; Lee MA; Kwek ZP; Joy J; Anantharajan J; Baburajendran N; Pendharkar V; Manoharan V; Vuddagiri S; Sangthongpitag K; Hill J; Keller TH; Hung AW
Bioorg Med Chem; 2021 Nov; 49():116437. PubMed ID: 34600239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]